TOP HEADLINES

Featured Story

  • Merck, Lilly, Pfizer top $1B doc-payments list

    Drugmakers forked over more than $1 billion to doctors last year, significantly more than reported in 2011. And that's only the amounts we know about. According to a new data analysis by PharmaShine, reported in the Financial Times, that figure only includes the 12 leading drugmakers that actually disclose physician payments.

Daiichi accuses Ranbaxy shareholders of hiding info before buyout

Ranbaxy Laboratories' FDA woes may soon be over now that the drugmaker has forked over a $500 million settlement to the federal government. It seems owner Daiichi Sankyo's Ranbaxy woes, however, are anything but. The Japanese company now believes former Ranbaxy shareholders withheld key info when negotiating to sell Daiichi its majority stake in the Indian drugmaker.

FDA ban could cost India's Wockhardt $100 million

An FDA import ban can be costly, and India's Wockhardt says the import alert it is now under could slice $100 million out of its revenues.

Why is the FDA holding Avandia hearings? Agency critic has ideas

Publicly disgraced after cardiologist Steven Nissen and his colleagues unveiled data on its cardiovascular risks in 2007, Avandia was withdrawn in Europe and put under tight rein in the U.S. Now, the FDA is revisiting the issue, and Nissen himself has issues with that.

Ranbaxy said to be eyeing major cuts to sales force, mainly in U.S.

The company is considering cutting back its field force of about 14,600 by as much as one-third, the sources said.

Pfizer offers share exchange to grant Zoetis its freedom

Pfizer is cutting the apron strings at Zoetis. Just months after its highly successful IPO, in which Pfizer sold off a 20% stake, the animal health business is set to become fully independent. Pfizer is offering a stock swap to its shareholders, who can exchange $100 in Pfizer shares for roughly $107 worth of Zoetis stock.

MORE NEWS

From Our Sister Sites

FierceBiotech

Scientists failed to replicate the tantalizing evidence of efficacy from a study of the cancer drug bexarotene in mouse models of Alzheimer's disease, throwing cold water on efforts to advance the approved anti-tumor therapy for patients with the memory-stealing illness.

FierceCRO

Nordion's constantly evolving business will soon be without proprietary pharma, as the company has agreed to ship out its targeted therapies business for $200 million.